News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Daiwa Lifts INNOVENT BIO's TP to HKD95, Reiterates Rating Buy
Daiwa has published a report reiterating a Buy rating on INNOVENT BIO (01801.HK) and raising the target price from HKD58 to HKD95 based on a discounted cash flow valuation.The brok...
Reset
Send
The window will close in 5 seconds
<Research>Daiwa Lifts INNOVENT BIO's TP to HKD95, Reiterates Rating Buy
Close
Recommend
29
Positive
37
Negative
17
 
SHORT SELL
 
STOCK INFO

Daiwa has published a report reiterating a Buy rating on INNOVENT BIO (01801.HK)  -0.200 (-0.233%)    Short selling $114.29M; Ratio 16.500%   and raising the target price from HKD58 to HKD95 based on a discounted cash flow valuation.

The broker based its decisions on the inclusion of the IBI363 drug's value following the American Society of Clinical Oncology's annual meeting. It is now forecasted to be launched in China and globally in 2028 and 2029, with risk-adjusted peak sales estimated at around RMB4 billion and USD2.2 billion by 2035.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-16 12:25.)

Related NewsHSBC Research Lists Asia Best Stock Ideas in 3Q (Table)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.